NASDAQ$ADUS
Addus HomeCare Corporation · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
Addus HomeCare reported strong financial results for the fourth quarter and full year ended December 31, 2024, with significant revenue growth and increased profitability.
Addus HomeCare announced a strong finish to 2024, with fourth-quarter net service revenues growing 7.5% to $297.1 million and adjusted EBITDA increasing 10.3% year-over-year to $37.8 million. The company also completed the acquisition of Gentiva's personal care operations, significantly expanding its market presence.
- Net service revenues increased 7.5% year-over-year to $297.1 million in Q4 2024.
- Adjusted EBITDA grew 10.3% to $37.8 million in Q4 2024.
- Adjusted net income per diluted share increased 4.6% to $1.38 in Q4 2024.
- The acquisition of Gentiva's personal care operations was completed, adding approximately $280 million in annualized revenues and expanding market coverage to new states.
Headline financials
Revenue & EPS history
Addus · Revenue · Quarterly
$297M
Revenue by segment
Addus · $271M total across 3 segments · Q3 2023
- Personal Care$202M+12.7%74.6%
- Hospice$53.1M+3.4%19.6%
- Home Health$15.7M+57.9%5.8%
Forward guidance
Addus HomeCare is optimistic about additional acquisition opportunities in 2025 and plans to maintain a disciplined approach to growth, focusing on expanding coverage and building scale in strategic markets, particularly where they can leverage their personal care network and add clinical services.
Tailwinds
- Optimistic about additional acquisition opportunities in 2025.
- Will maintain a disciplined approach to acquisitions, identifying prospects that are a good strategic fit.
- Primary focus on markets where personal care network can be leveraged to add clinical services.
- Believes having three levels of care provides a distinct competitive advantage and strengthens ability to negotiate more effectively with payers.
- Well-positioned for continued growth and committed to delivering greater value to shareholders.
Headwinds
- No specific negative forward guidance was provided in the report.
- Potential risks include discretionary determinations by government officials.
- Uncertainty regarding the outcome of discussions with managed care organizations.
- Changes in government regulations and reimbursement trends could impact results.
- Higher than anticipated costs or lower than anticipated cost savings could affect financial performance.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2024
+1.2%
Avg return
Earnings day
+2.3%
Avg return
5 days after
+5.0%
Avg return
30 days after
58%
37 / 64 earnings
Positive
+23.7%
Q4 2019
Best reaction
-19.6%
Q4 2013
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.7% | -0.6% | -10.6% | |
| Q4 2025 | -9.1% | -12.0% | -17.0% | |
| Q3 2025 | -5.9% | -5.0% | -4.1% | |
| Q1 2025 | +4.1% | +6.3% | +7.5% | |
| Q4 2024 | -10.4% | -12.0% | -10.1% | |
| Q3 2024 | -1.7% | +1.0% | -2.1% | |
| Q2 2024 | +3.5% | +3.6% | +8.5% | |
| Q1 2024 | +6.5% | +11.3% | +16.8% | |
| Q4 2023 | +3.4% | +5.3% | +16.4% | |
| Q3 2023 | -3.7% | +3.3% | +7.0% | |
| Q2 2023 | +1.2% | +3.9% | -0.1% | |
| Q1 2023 | +5.8% | +0.3% | +10.3% | |
| Q4 2022 | +3.9% | +2.5% | -0.4% | |
| Q3 2022 | +3.1% | +3.8% | +4.8% | |
| Q2 2022 | +3.1% | +0.6% | -3.9% | |
| Q1 2022 | -2.3% | -4.7% | -4.2% | |
| Q4 2021 | +20.5% | +20.4% | +15.8% | |
| Q3 2021 | -0.5% | +9.1% | -8.9% | |
| Q2 2021 | +9.1% | +5.3% | +4.0% | |
| Q1 2021 | -6.6% | -8.1% | -10.0% | |
| Q4 2020 | -11.3% | -14.2% | -11.3% | |
| Q3 2020 | +11.9% | +10.3% | +4.6% | |
| Q2 2020 | +2.7% | -4.6% | -7.1% | |
| Q1 2020 | +10.2% | +2.7% | +22.5% | |
| Q4 2019 | +23.7% | +8.5% | +42.1% | |
| Q3 2019 | -0.9% | -0.1% | +8.6% | |
| Q2 2019 | +1.4% | +4.4% | -0.2% | |
| Q1 2019 | +3.6% | +3.0% | +8.8% | |
| Q4 2018 | -2.8% | -7.8% | -3.8% | |
| Q3 2018 | +6.5% | +10.8% | +16.7% | |
| Q2 2018 | -4.4% | -7.1% | -3.4% | |
| Q1 2018 | +3.1% | +1.8% | +11.9% | |
| Q4 2017 | -0.3% | +8.6% | +38.5% | |
| Q3 2017 | -1.4% | -5.8% | -7.8% | |
| Q2 2017 | -0.3% | -1.4% | -1.3% | |
| Q1 2017 | +11.3% | +9.4% | +2.6% | |
| Q4 2016 | +1.2% | +0.1% | -7.5% | |
| Q3 2016 | +17.4% | +28.7% | +32.7% | |
| Q2 2016 | +13.8% | +8.6% | +27.1% | |
| Q1 2016 | -1.1% | — | — | |
| Q4 2015 | -16.6% | — | — | |
| Q3 2015 | -12.7% | — | — | |
| Q2 2015 | +4.4% | — | — | |
| Q1 2015 | -3.4% | — | — | |
| Q4 2014 | +3.7% | — | — | |
| Q3 2014 | +7.1% | — | — | |
| Q2 2014 | +1.3% | — | — | |
| Q1 2014 | +1.8% | — | — | |
| Q4 2013 | -19.6% | — | — | |
| Q3 2013 | +4.3% | — | — | |
| Q2 2013 | +9.3% | — | — | |
| Q1 2013 | +0.9% | — | — | |
| Q4 2012 | +13.2% | — | — | |
| Q3 2012 | +10.5% | — | — | |
| Q2 2012 | +1.1% | — | — | |
| Q1 2011 | -0.0% | — | — | |
| Q1 2012 | -7.8% | — | — | |
| Q4 2011 | +6.6% | — | — | |
| Q3 2010 | -1.3% | — | — | |
| Q3 2011 | -1.3% | — | — | |
| Q2 2011 | -17.3% | — | — | |
| Q2 2010 | -17.3% | — | — | |
| Q4 2010 | +0.2% | — | — | |
| Q1 2010 | +2.6% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro